Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl

https://doi.org/10.1016/j.bmcl.2008.09.071Get rights and content

Abstract

The cytotoxic macrolide kendomycin was identified as a ligand of Bcl-xl, an anti-apoptotic member of the Bcl-2 protein family. Hydrolysis-stable and protonable semi-synthetic analogues have been obtained that retain cytotoxicity and Bcl-xl binding.

Graphical abstract

Discovery of a stable and soluble Bcl-xl inhibitor derived from kendomycin has been disclosed.

  1. Download : Download full-size image

Section snippets

Acknowledgments

The authors acknowledge the contributions of Drs. Yoganathan and Mark Butler for the original isolation of kendomycin.

References and notes (18)

  • M.P. Kline

    Leukemia

    (2007)
  • Funahashi, Y. et al. Japanese Patent 08,231,551, 1996; Chem. Abstr. 1997, 126,...
  • G. Kroemer

    Nat. Med.

    (1997)
    J.M. Adams et al.

    Science

    (1998)
  • S.A. Amundson

    Cancer Res.

    (2000)
  • J. O’Neill

    Biochim. Biophys. Acta

    (2004)
  • T. Oltersdorf

    Nature

    (2005)
  • J.S. Sturla

    Cancer Res.

    (2007)
  • M. Feher et al.

    J. Chem. Inf. Comput. Sci.

    (2002)
  • M.S. Butler

    Nat. Prod. Rep.

    (2005)
There are more references available in the full text version of this article.

Cited by (0)

View full text